Radius Health, RDUS is showing recent insider trading activity. Public SEC records indicate that Rubric Capital Management LP recently Bought $40,401 worth of shares on 2 months ago. With that said, our editors here at healthtechmovers.com, are adding RDUS to our watchlist to see if this momentum continues.
Based on this transaction and a few others from Corporate Insiders of RDUS that Bought $2.7M worth of shares in the last 3 months, the Insider Confidence level of Radius Health is trending Up.
Since these insiders have unique insights into what's happening at Radius Health, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for RDUS:
In addition, TradingView issued a Buy rating for RDUS over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook.
Here is a bit more on Radius Health, RDUS but please do your own research.
RDUS Summary: Radius Health, Inc. is a biopharmaceutical company, focused on the development of endocrine therapeutics in the areas of osteoporosis and oncology. In April 2017, the FDA approved Tymlos (abaloparatide -SC) injection for the treatment of postmenopausal women with high risk osteoporosis for fracture - defined as history of osteoporotic fracture - multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to RDUS, you should consider joining TipRanks.com.
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
Based on this transaction and a few others from Corporate Insiders of RDUS that Bought $2.7M worth of shares in the last 3 months, the Insider Confidence level of Radius Health is trending Up.
Since these insiders have unique insights into what's happening at Radius Health, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for RDUS:
- Rubric Capital Management LP - >10% Owner, Bought $40,401 worth of shares on 1 day ago
- BIOTECH TARGET N V - >10% Owner, Bought $2,656,701 worth of shares on 2 months ago
- BIOTECH TARGET N V - >10% Owner, Bought $3,465,500 worth of shares on 7 months ago
- Rubric Capital Management LP - >10% Owner, Bought $1,037,063 worth of shares on 7 months ago
In addition, TradingView issued a Buy rating for RDUS over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook.
Here is a bit more on Radius Health, RDUS but please do your own research.
RDUS Summary: Radius Health, Inc. is a biopharmaceutical company, focused on the development of endocrine therapeutics in the areas of osteoporosis and oncology. In April 2017, the FDA approved Tymlos (abaloparatide -SC) injection for the treatment of postmenopausal women with high risk osteoporosis for fracture - defined as history of osteoporotic fracture - multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
- Recent Last Price: $10.1
- Price Change: $0.02, 0.2%
- Yearly Gain: -26.90%
- Market Cap: $479.81M
- P/E Ratio: -6.961
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to RDUS, you should consider joining TipRanks.com.
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================